Pages that link to "Q24596282"
Jump to navigation
Jump to search
The following pages link to Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid (Q24596282):
Displaying 50 items.
- Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice (Q21090483) (← links)
- Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection (Q21142645) (← links)
- Epigenetic control of HIV-1 post integration latency: implications for therapy (Q26781191) (← links)
- Impact of Chromatin on HIV Replication (Q26782046) (← links)
- Manipulation of the host protein acetylation network by human immunodeficiency virus type 1 (Q26795463) (← links)
- Redefining the viral reservoirs that prevent HIV-1 eradication (Q26827255) (← links)
- HIV-1 eradication strategies: design and assessment (Q26864933) (← links)
- Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure? (Q26995220) (← links)
- Recent developments in human immunodeficiency virus-1 latency research (Q27013114) (← links)
- Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers (Q27312050) (← links)
- Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes (Q27324527) (← links)
- Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner (Q28474468) (← links)
- Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing (Q28537694) (← links)
- An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients (Q28538015) (← links)
- Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA (Q28541244) (← links)
- Latency reversal and viral clearance to cure HIV-1. (Q30248766) (← links)
- The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines. (Q30368366) (← links)
- A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. (Q30385378) (← links)
- Therapy for persistent HIV. (Q30386370) (← links)
- Eradication therapies for HIV Infection: time to begin again (Q30399588) (← links)
- Prospects for treatment of latent HIV. (Q30424413) (← links)
- Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells (Q31036545) (← links)
- Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs (Q31158755) (← links)
- Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection (Q33476165) (← links)
- A novel HIV-1-encoded microRNA enhances its viral replication by targeting the TATA box region (Q33556837) (← links)
- Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication (Q33589167) (← links)
- Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy (Q33627137) (← links)
- Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals (Q33627182) (← links)
- Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder (Q33694166) (← links)
- Newly emerging therapies targeting viral-related lymphomas (Q33699201) (← links)
- Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. (Q33838633) (← links)
- Combinatorial latency reactivation for HIV-1 subtypes and variants (Q33877492) (← links)
- Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. (Q33883423) (← links)
- No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy (Q33921146) (← links)
- Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1 (Q34132738) (← links)
- Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice (Q34180174) (← links)
- Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells (Q34218827) (← links)
- Cell line-dependent variability in HIV activation employing DNMT inhibitors (Q34243934) (← links)
- Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy (Q34290545) (← links)
- Framing expectations in early HIV cure research (Q34363988) (← links)
- Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB (Q34482017) (← links)
- Finding a cure for HIV: will it ever be achievable? (Q34567084) (← links)
- Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques (Q34596417) (← links)
- Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies (Q34607763) (← links)
- Towards an HIV cure: a global scientific strategy (Q34640562) (← links)
- Interaction between endogenous bacterial flora and latent HIV infection (Q34686713) (← links)
- Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients (Q34700900) (← links)
- Plasmodium infection reduces the volume of the viral reservoir in SIV-infected rhesus macaques receiving antiretroviral therapy (Q34722464) (← links)
- Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay (Q34758220) (← links)
- Histone deacetylase inhibitors and HIV latency (Q34816844) (← links)